Everything below concerns vaccine adjuvant. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
A diener is a morgue worker responsible for handling, moving, and cleaning the corpse. In the UK, the equivalent job title is "mortuary assistant", whilst the preparation, evisceration and reconstruction of the deceased is performed by an anatomical pathology technician. In the US, dieners are also referred to as "mortuary assistants" or "autopsy technicians". The word is derived from the German word Leichendiener, which literally means corpse servant (diener means servant.). A diener performs a number of tasks in medical schools and morgues. Helping a pathologist with examining and reconstructing cadavers are main tasks performed by a diener. A diener assists a pathologist or physician during an autopsy completing tasks such as handling tools and supplies cuting in to them and preparation of the deceased before and after autopsy. In addition to physical work with a pathologist and cadavers, dieners do work such as record keeping of identification and documentation of deceased in the form of items such as death certificates. In the American Moravian Church (German: Herrnhuter Brüdergemeine), the men and (particularly) the women who assist in church services (like the Lovefeast) are called "dieners", from the German title for their office, Saaldiener or "chapel servant".
Here, phenyllithium 1 attacks the carbonyl group of DMF 2, giving tetrahedral intermediate 3. Because the dimethylamide anion is a poor leaving group, the intermediate does not collapse and another nucleophilic addition does not occur. Upon acidic workup, the alkoxide is protonated to give 4, then the amine is protonated to give 5. Elimination of a neutral molecule of dimethylamine and loss of a proton give benzaldehyde, 6. A new class of amide reactions was discovered in 2015 by the research teams of Neil Garg and Ken Houk, showing that amides can be converted to esters using nickel catalysis. The nickel catalyst breaks the ordinarily strong amide C-N bond through oxidative addition. Many other amide cross-couplings were subsequently developed using nickel or palladium catalysis, including Suzuki-Miyaura couplings, allowing for amides to be readily converted to numerous other functional groups.
== See also == 6,14-Endoethenotetrahydrooripavine - the central nucleus of all Bentley compound opioids under which class etorphine falls 7-PET Dihydroetorphine – a close analog of etorphine that has been used as an opioid painkiller for human use in China Thienorphine Opioid potency comparison
In addition, Brazil already managed a peacekeeping mission in Haiti ($350 million) and makes in-kind contributions to the World Food Programme ($300 million). The scale of this aid places it on par with China and India. The Brazilian South-South aid has been described as a "global model in waiting".
=== Political === Immediately following the arrests, strong reactions of condemnation of Vice-President Kaili came from around the European Union. After the story was first reported by Belgian media, the President of the European Parliament, Roberta Metsola, stated that the European Parliament had been complying with an ongoing investigation, without specifying its nature. Immediately following the arrests, both PASOK, Kaili's political party in Greece, and the Socialists and Democrats Group inside the European Parliament announced Kaili's suspension from their respective parties. Two days following the arrests, Metsola suspended Kaili's responsibilities and powers as a Vice-President of the European Parliament. Three days later, in a vote of the full chamber, Kaili was officially removed as vice president by a supermajority. At the opening of the first meeting of the European Parliament following the raids, on 12 December President Metsola announced that all work with Qatar would be suspended. The suspension of Parliamentary business at such a time was significant as it comes just three days before the Parliament was due to vote on introducing a visa-free travel agreement with Qatar and other countries. This resulted in the vote on visa-free travel to Ecuador, Kuwait, and Oman also being cancelled. In addition, a major and controversial air transit agreement that would have allowed Qatar Airways unlimited access to the EU market was put on hold after warning that Qatar may have interfered in Parliament's internal deliberations on the agreement.
Sources: en.wikipedia.org
==== Hierarchical deterministic wallet ==== The hierarchical deterministic (HD) wallet was publicly described in BIP32. As a deterministic wallet, it derives keys from a single master root seed, but instead of having a single "chain" of key pairs, an HD wallet supports multiple independent key pair chains. This allows a single seed to be used to generate an entire tree of key pairs with a stratified structure.
=== Inflammatory and immune-related diseases === Microbial therapeutics are being studied for the treatment of inflammatory and immune-related diseases, including inflammatory bowel disease (IBD), allergies, and autoimmune disorders. In these conditions, the immune system becomes overactive or poorly regulated, leading to chronic inflammation. Certain microorganisms can help reduce inflammation by promoting immune balance. For example, some gut microbes produce molecules that calm inflammatory immune responses or support immune cells that help prevent excessive inflammation. Researchers are also developing engineered microorganisms that can release anti-inflammatory substances directly at sites of inflammation, which may reduce side effects compared with treatments that affect the entire body.
Non-pathogenic organisms can become pathogenic given specific conditions, and even the most virulent organism requires certain circumstances to cause a compromising infection. Some colonizing bacteria, such as Corynebacteria sp. and Viridans streptococci, prevent the adhesion and colonization of pathogenic bacteria and thus have a symbiotic relationship with the host, preventing infection and speeding wound healing.
== Specific diseases caused by point mutations == Point mutations—single‑base changes in the DNA sequence—are one of the most common molecular causes of human disease. By altering a single nucleotide, these mutations can substitute one amino acid for another, introduce premature stop codons, or disrupt normal splicing signals. Depending on where they occur and how they affect the encoded protein, point mutations may abolish enzyme activity, destabilize structural domains, or impair regulatory interactions. In many inherited disorders, a single missense or nonsense substitution is enough to trigger a cascade of biochemical failures, leading to early‐onset or lifelong symptoms. In cancer, somatic point mutations can inactivate tumor suppressors or hyperactivate oncogenes, fueling uncontrolled cell growth. Across the human genetic landscape, thousands of point‐mutation–driven conditions have been cataloged—from relatively common disorders like sickle‐cell anemia and cystic fibrosis to extremely rare syndromes that affect only a handful of families worldwide. Although each disease has its own pathophysiological details, they share a unifying theme: a precisely localized change in the gene sequence can compromise protein function in a way that no larger chromosomal rearrangement or copy‐number alteration could. Because point mutations are often amenable to targeted genetic testing, they also highlight how molecular diagnosis and personalized therapies (e.g., small molecules that stabilize a mutant enzyme) rely on knowing exactly which codon is altered.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。